Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2020
August 11, 2020 at 02:18 pm EDT
Share
SynCore Biotechnology Co.,Ltd announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced sales was TWD 1.658 million compared to TWD 2.330 million a year ago. Operating loss was TWD 109.369 million compared to TWD 123.835 million a year ago. Net loss was TWD 109.738 million compared to TWD 122.053 million a year ago. Basic loss per share was TWD 1.08 compared to TWD 1.46 a year ago. For the half year, sales was TWD 3.740 million compared to TWD 8.802 million a year ago. Operating loss was TWD 194.547 million compared to TWD 188.035 million a year ago. Net loss was TWD 194.270 million compared to TWD 185.582 million a year ago. Basic loss per share was TWD 1.91 compared to TWD 2.23 a year ago.
SynCore Biotechnology Co.,Ltd is a Taiwan-based company principally engaged in the research, development, production and sales of therapeutic drugs. The Company's main product is SB03 Veregen. The Company is also involved in research, development and clinical trials of the injection-type anticancer drug, SB01 and the oral anticancer drug, SB01. The Company distributes its products mainly in domestic market.